PTAB designates seven IPR decisions as “informative”

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

PTAB designates seven IPR decisions as “informative”

ptab-web-icon.jpg

The Patent Trial and Appeal Board has designated seven of its decisions rendered in inter partes review (IPR) proceedings as “informative”

uspto.jpg

In each decision, the PTAB denied institution of an IPR under 35 USC § 325(d), which permits the Director to take into account whether, and reject the petition or request because, the same or substantially the same prior art or arguments previously were presented.

The seven decisions are:

Medtronic, Inc v Nuvasive Inc., Paper 8, No. IPR2014-00487 (September 11 2014)

Unified Patents Inc v PersonalWeb Techs., LLC, Paper 13, No. IPR2014-00702 (July 24 2014)

Prism Pharma Co v Choongwae Pharma Corp., Paper 14, No. IPR2014-00315 (July 8 2014)

Unilever, Inc v Procter & Gamble Co., Paper 17, No. IPR2014-00506 (July 7 2014)

Medtronic, Inc v Robert Bosch Healthcare Systems, Inc., Paper 17, No. IPR2014-00436 (June 19 2014)

Intelligent Bio-Systems Inc. v Illumina Cambridge Limited, Paper 19, No. IPR2013-00324 (November 21 2013)

ZTE Corp v ContentGuard Holdings, Inc., Paper 12, No. IPR2013-00454 (25 September 25 2013)

Decisions designated as "informative" can be viewed here.


more from across site and SHARED ros bottom lb

More from across our site

The firm launched a San Diego office earlier this month, but California investment and expansion is far from complete
The industry’s response to AI requires an unfamiliar ingredient as firms battle to shape their futures
The firm is looking beyond replacing recently departed talent, betting instead on senior leaders to strengthen and expand its patent litigation platform
Olga Partington, director in Sterne Kessler’s biotechnology and chemical practice group, shares why a patent's vulnerability peaks when it is young, rather than when it is most valuable, under the PTAB's new framework
IP experts gathered in San Francisco last week to discuss the changing global SEP landscape and new licensing models for AI infrastructure
SKW Schwarz partner Daniel Kendziur explains how new green claims rules are changing his workload and bringing him into direct contact with marketing, PR and government affairs teams
The government is targeting earlier resolution of SEP disputes while ruling out a standalone IPEC rate determination track and restrictions on injunctions
Ana Castedo, who brings a strong focus on patent litigation, will help build the firm’s IP litigation offering in Madrid
A former scientist, inventor and now a patent practice leader, Hanane Fathi Roswall shares her views on leadership, diversity, the rise of AI and the promise of the UPC
With rumours that a third IP judge could yet join the England and Wales High Court, we run through some potential names while practitioners outline the importance of a well-stocked bench
Gift this article